MEXAZOLAM

Possibly Marketed Outside US

Details

Stereochemistry	MIXED
Molecular Formula	C18H16Cl2N2O2
Molecular Weight	363.238
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1COC2(N1CC(=O)NC3=CC=C(Cl)C=C23)C4=C(Cl)C=CC=C4

InChI

InChIKey=ANUCDXCTICZJRH-UHFFFAOYSA-N

InChI=1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)

HIDE SMILES / InChI

Description

Mexazolam (trade names Melex and Sedoxil) is indicated for the management of anxiety with or without psychoneurotic conditions. In adult patients, the recommended daily dosage of mexazolam is 1-3 mg, administered three times daily. Mexazolam is metabolised via the CYP3A4 pathway.

Approval Year

Conditions

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety	Curative		Phase III	Unknown

Doses

Show entries

Dose	Population	Adverse events
1 mg 3 times / day multiple, oral	unhealthy	Other AEs: Drowsiness...

Showing 1 to 1 of 1 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Drowsiness	8 patients	1 mg 3 times / day multiple, oral	unhealthy

Showing 1 to 1 of 1 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor substrate	inhibitor substrate	substrate inhibitor	inhibitor

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 CYP1A2	CYP2C CYP1A CYP2C11 CYP2B6 CYP3A5 CYP1A2 CYP2A6 CYP2C8 CYP2E1

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP1A2	inhibitor	no
CYP3A4	inhibitor	yes [IC50 1.3803 uM]
CYP2D6	inhibitor	yes [IC50 10.964 uM]
CYP2C9	inhibitor	yes [IC50 24.5454 uM]
CYP2C19	inhibitor	yes [IC50 4.3649 uM]

Showing 1 to 5 of 5 entries

Previous1Next

Drug as victim

Show entries

Target	Modality	Activity
CYP1A	substrate	no
CYP1A2	substrate	no
CYP2A6	substrate	no
CYP2C	substrate	no
CYP2C8	substrate	no

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
hERG	inhibitor

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder.	2003	17535036
Passiflora for anxiety disorder.	2007 Jan 24	17253512
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.	2010 Jun 15	20579469

Showing 1 to 4 of 4 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

1-3 mg, administered three times daily

Route of Administration: Oral

In Vitro Use Guide

Unknown

Show entries

Name

Type

Language

MEXAZOLAM

Official Name

English

MEXAZOLAM [MART.]

Common Name

English

10-CHLORO-11B-(O-CHLOROPHENYL)-2,3,7,11B-TETRAHYDRO-3-METHYLOXAZOLO(3,2-D)(1,4)BENZODIAZEPIN-6(5H)-ONE

Common Name

English

mexazolam [INN]

Common Name

English

MEXAZOLAM [MI]

Common Name

English

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Antianxiety Agent

NCI_THESAURUS

C1012

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

DRUG BANK

DB15489

PRIMARY

EPA CompTox

DTXSID9057715

PRIMARY

EVMPD

SUB08929MIG

PRIMARY

WIKIPEDIA

Mexazolam

PRIMARY

INN

4526

PRIMARY

Showing 1 to 5 of 13 entries

Previous1 2 3Next

ACTIVE MOIETY


					S5969B6237

MEXAZOLAM

SMILES

InChI

Approval Year

Conditions

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Drug as perpetrator